Graves’ Hastalığına Sahip Olgularda Tiroid Maligniteleri

Yıl 2016, Cilt: 43 Sayı: 3, 460 - 467, 01.09.2016

Hasan Güçer

Öz

Amaç: Graves’ hastalığı otoimmün bir tiroid hastalığıdır.
Eş zamanlı primer tiroid maligniteleri ile Graves’ hastalığı
birlikteliği, giderek artan bir sıklıkta bildirilmektedir. Çalışmanın
amacı laboratuarımızda incelenen Graves’ hastalığına
sahip olguların tiroidektomi materyallerinde tiroid
malignitesi sıklığını araştırmaktır.
Yöntemler: 2010-2016 yılları arasında Recep Tayyip Erdoğan
Üniversitesi Eğitim ve Araştırma Hastanesi Patoloji
Laboratuarı’na Graves’ hastalığı nedeni ile gönderilen
kırk (40) adet tiroidektomi materyaline ait preparat örnekleri
yeniden incelendi.
Bulgular: Kırk adet tiroidektomi materyalinin 11 (%27,5)
tanesinde malignite saptandı. Malignitelerin tümü papiller
karsinomdu. Makroskopik ya da mikroskopik olarak nodüle
sahip Graves hastalıklı olgularda malignite sıklığı, nodülü
olmayan gruba göre daha yüksek bulundu (p<0.05).
Sonuç: Literatür ile uyumlu olarak, bu çalışmada da, Graves’
hastalığında nodül varlığının malignite riskini artırdığı
gösterilmiştir. Nodüle sahip Graves’ hastaları klinik, radyolojik
ve patolojik olarak dikkatli araştırılmalıdır

Anahtar Kelimeler

Graves’ hastalığı, tiroid karsinomu, insidental

Thyroid Malignancies In Patients With Graves Disease

Öz

Objective: Graves’ disease is an autoimmune thyroid disorder. Concurrent Graves’ disease with primary thyroid malignancies has been reported at an increasing frequen­cy. The aim of this study is to investigate the prevalence of primary thyroid malignancies among thyroidectomy specimens with Graves’ disease examined in our depart­ment. Methods: The slides of forty patients, which underwent thyroidectomy due to Graves’ disease, were reevaluated in between 2010 to 2016. Results: 11 of 40 thyroidectomy specimens (27.5%) had primary thyroid malignancy. All malignancies were papil­lary carcinoma. The prevalence of malignancy was sig­nificantly higher in cases of Graves’ disease with mac­roscopic or microscopic nodule than in Graves’ patients without nodule (p<0.05). Conclusion: This study also showed that the Graves’ disease with nodule had more risk of thyroid malignancy. The patients with concurrent Graves’ disease and thyroid nodule should be carefully examined clinically, radiologi­cal, and pathologically for thyroid cancer.

Anahtar Kelimeler

Graves’ disease, thyroid carcinoma, incidental

Kaynakça

• 1. Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease. Autoimmun Rev. 2014;13:398-402.
• 2. Cantalamessa L, Baldini M, Orsatti A, et al. Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Arch Intern Med. 1999;159:1705-8.
• 3. Erbil Y, Barbaros U, Ozbey N, et al. Graves’ disease, with and without nodules, and the risk of thyroid carcinoma. J Laryngol Otol. 2008;122:291-5.
• 4. Tam AA, Kaya C, Kilic FB, et al. Thyroid nodules and thyroid cancer in Graves’ disease. Arq Bras Endocrinol Metabol. 2014;58:933-8.
• 5. Boutzios G, Vasileiadis I, Zapanti E et al. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves’ Disease. Thyroid. 2014;24:347-54.
• 6. Chen YK, Lin CL, Chang YJ, et al. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid. 2013;23:879-84.
• 7. Ergin AB, Saralaya S, Olansky L. Incidental papillary thyroid carcinoma: clinical characteristics and prognostic factors among patients with Graves’ disease and euthyroid goiter, Cleveland Clinic experience. Am J Otolaryngol. 2014;35:784-90.
• 8. Gerenova J, Buysschaert M, de Burbure CY, Daumerie C. Prevalence of thyroid cancer in Graves’ disease: a retrospective study of a cohort of 103 patients treated surgically. European Journal of Internal Medicine. 2003;14:321-5.
• 9. Lee J, Nam KH, Chung WY, et al. Clinicopathologic features and treatment outcomes in differentiated thyroid carcinoma patients with concurrent Graves’ disease. J Korean Med Sci. 2008;23:796-801.
• 10. Phitayakorn R, McHenry CR. Incidental thyroid carcinoma in patients with Graves’ disease. Am J Surg. 2008;195:292- 7; discussion 7.
• 11. Ren M, Wu MC, Shang CZ, et al. Predictive factors of thyroid cancer in patients with Graves’ disease. World J Surg. 2014;38:80-7.
• 12. Staniforth JU, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves’ disease: A meta-analysis. Int J Surg. 2016;27:118-25.
• 13. Tamatea JA, Tu’akoi K, Conaglen JV, et al. Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? ANZ J Surg. 2014;84:231-4.
• 14. Wei S, Baloch ZW, LiVolsi VA. Thyroid carcinoma in patients with Graves’ disease: an institutional experience. Endocr Pathol. 2015;26:48-53.
• 15. LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004;11:279-87.
• 16. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56:531-8.
• 17. Bradly DP, Reddy V, Prinz RA, Gattuso P. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery. 2009;146:1099-104.
• 18. Mishra A, Mishra SK. Thyroid nodules in Graves’ disease: implications in an endemically iodine deficient area. J Postgrad Med. 2001;47:244-7.
• 19. Pellegriti G, Mannarino C, Russo M, et al. Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab. 2013;98:1014-21.
• 20. Preece J, Grodski S, Yeung M, et al. Thyrotoxicosis does not protect against incidental papillary thyroid cancer. Surgery. 2014;156:1153-6.
• 21. Senyurek Giles Y, Tunca F, Boztepe H, et al. The risk factors for malignancy in surgically treated patients for Graves’ disease, toxic multinodular goiter, and toxic adenoma. Surgery. 2008;144:1028-36; discussion 36-7.
• 22. Smith JJ, Chen X, Schneider DF, et al. Cancer after thyroidectomy: a multi-institutional experience with 1,523 patients. J Am Coll Surg. 2013;216:571-7; discussion 7-9.
• 23. Taşkesen F, Uslukaya Ö, Kuzu H, et al. Coexistence of hyperthyroidism and thyroid cancer. Dicle Tıp Dergisi. 2014;41:364-7.
• 24. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev. 1998;19:673-716.
• 25. Belfiore A, Garofalo MR, Giuffrida D, et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab. 1990;70:830-5.
• 26. Karagülle E, Türk E, Ayvazoğlu Soy E, et al. Bir merkezde tiroid papiller mikrokarsinom görülme sıklığı ve ameliyat öncesi tetkiklerin tanısal değeri. Diyaliz Transplantasyon ve Yanık. 2009;20:22-8.
• 27. Kim SH, Kim HY, Jung KY, et al. Anaplastic thyroid carcinoma following radioactive iodine therapy for graves’ disease. Endocrinol Metab (Seoul). 2013;28:61-4.
• 28. Meng ZW, Zhang YJ, Li W, et al. Relapse of hyperthyroidism after hemithyroidectomy in concurrent medullary thyroid cancer and Graves’ disease. Bratisl Lek Listy. 2013;114:544-6.
• 29. Baloch Z, LiVolsi VA, Tondon R. Aggressive variants of follicular cell derived thyroid carcinoma; the so called ‘real thyroid carcinomas’. J Clin Pathol. 2013;66:733-43.
• 30. Chai EZ, Siveen KS, Shanmugam MK, et al. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J. 2015;468:1-15.
• 31. Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150:49-52.
• 32. Chui MH, Cassol CA, Asa SL, Mete O. Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Arch. 2013;462:557-63.
• 33. Montone KT, Baloch ZW, LiVolsi VA. The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med. 2008;132:1241-50.
• 34. Guth S, Theune U, Aberle J, et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39:699-706.
• 35. Anderson SR, Mandel S, LiVolsi VA, et al. Can cytomorphology differentiate between benign nodules and tumors arising in Graves’ disease? Diagnostic Cytopathology. 2004;31:64-7.